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Introduction
Wilson’s disease (WD) is an autosomal recessive disorder 
resulting from the mutation of ATP7B gene [2].  The WD gene 
consists of 21 exons that span a genomic region of about 80 kb 
and is located on the long arm of chromosome 13 (13q14.1) [5, 
35].  ATP7B encodes a large membrane protein of 1.465 amino 
acids that has been characterized to be a copper-transporting 
P-type adenosine triphosphatase (ATPase) which has a high 
homology of the amino acid sequence of the genes respon-
sible for Menkes’ disease.  Worldwide, the frequency of WD 
is approximately 1:30 000.  ATP7B is mainly expressed in 
the liver and to a lesser extent in the brain and other organs. 
ATP7B has two functions in the liver which are central for the 
copper homeostasis [21].  ATP7B transports copper into the 
Trans Golgi Network (TGN) where the metal is transferred 
into apoceruloplasmin that is finally released into the blood 
as ceruloplasmin.  The excess of copper is sequestered by 
ATP7B in vesicles that are subsequently released from the 
body via bile canaliculi.
WD is a fatal disease when it is not appropriately treated, 
e.g. by anti-coppering drugs like penicillamine, and often leads 
to death [26, 31].  Hallmarks of WD are a copper accumula-
tion in liver, a low ceruloplasmin activity and the presence 
of Kayser-Fleischer corneal rings; though the diagnosis is 
difficult to be made since the individual abnormalities can 
be absent or on the borderline.  A wide spectrum of clinical 
presentations is observed, including a liver damage and/or 
neurologic/psychologic symptoms ranging from the patients 
with asymptomatic phenotypes, which show only mild ab-
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Abstract
Background: The impact of individual ATP7B mutations on the diversity of the clinical spectrum of Wilson’s disease (WD) is not understood yet.
Material and methods: The functional activity of ATP7B has been assessed and compared to the reports of the homozygous WD patients.  Ten rare 
and two frequent mutations H1069Q and R969Q have been selected after the analysis of the literature in question.  Chinese hamster ovary cell lines 
lacking ATP7B expression and carrying the selected mutations have been generated.  The cells have been characterized by transgenic ATP7B activity by 
the determination of copper accumulation and copper toxicity.
Results: The highly concordant results have been observed in the diverse functional activities of ATP7B within the groups of mutations that were 
established with regard to the disease onset reported in the patients.  Whereas a low (< 29 ± 3% of wild type of ATP7B) or no ATP7B activity has been 
found in the group of the mutations (n = 5) observed in the patients with early (or sudden) onset of the disease, its high activity (77.6 ± 7% to 118.6 ± 
7%) has been observed in the group of the patients with the late onset of the disease (n = 3).  Notably, the mutations H1069Q and R969Q of the third 
group (n = 4) showing predominately the intermediate time of the disease onset  have had a moderate level of ATP7B activity.
Conclusions: The data suggest that in the functional assessment of ATP7B mutations in homozygous patients we can single out the groups that have 
distinct grades of biologic activity which improves our understanding of the high degree of phenotypic variation observed in WD patients as well as the 
data on the onset of the disease.
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normalities of copper homeostasis, to the patients with liver 
cirrhosis, acute liver failure, mild psychologic symptoms or 
severe neurologic disability.  The onset of the disease is also 
highly variable and is often observed in childhood as well as 
in adolescence and even in elderly adults [9].  At present, the 
molecular mechanisms that underlie the complex clinical 
manifestation of WD have not been understood.  The carrier 
proteins such as metallothionine, gluthatione, superoxide 
dismutase and heat-shock proteins that mediate the uptake, 
delivery and efflux of copper have been implicated to modify 
the disease clinics.
It has been suggested that the type and location of a mu-
tation within ATP7B is a single determinant of the disease 
clinics indicating that the individual mutations of ATP7B may 
be linked to a phenotype.  More than 600 mutations of ATP7B 
are known and have been summarized in the public data base 
(www.hgmd.org).  The majority of mutations present missense 
mutations that are mostly located throughout the open reading 
frame of ATP7B, deletions and insertions; and other mutations 
leading to a premature stop codon are observed.  Since most 
WD patients have the compound mutations of ATP7B that 
may modulate the phenotypic expression of the disease by the 
two alleles which have distinct biologic activity, the analysis 
of homozygous mutations has helped our understanding in 
the investigation of the possible links of ATP7B genotype and 
phenotype, e.g. in the studies of the large families in specific 
regions [3].  While the frame shift and nonsense mutations 
of ATP7B have been implicated to result in the early onset 
and more severe manifestations of WD in various studies of 
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patients from Poland, Greece, and Germany [12, 28], such 
findings have been challenged by others [25, 27].  For some of 
the most frequently found homozygous missense mutations 
like H1069Q an association with late and predominantly 
neurological clinical presentation has been observed in WD 
patients [22, 9, 34], although such a link could not be detected 
in other cohorts [6, 10, 33].  The presence of uncharacterized 
disease-modifying factors has been postulated by the studies 
describing siblings and twins that have an identical mutation 
but different onsets and severity of the disease.  Therefore, it 
has been suggested that the conflicting reports include the 
observations of several ATP7B genotypes and are possibly 
caused by the disease modifying, e.g. due to ethnic or specific 
genetic factors of the region, alternate splicing, single nucle-
otide polymorphisms (SNP) and also by such factors as diet 
or lifestyle, that cannot be well controlled by a sole analysis of 
clinical data of WD patient cohorts.  Thus, in addition to the 
clinical studies of the patient cohorts a functional characteriza-
tion of ATP7B mutations has been helpful for understanding 
the impact of a given mutation [29, 14, 15 16].
We have addressed the question whether a functional 
characterization of ATP7B mutations may be suitable to 
classify the impact of an individual mutation on the clinical 
presentation when compared to the respective phenotype of 
homozygous WD patients.  A set of 12 mutations of ATP7B 
has been chosen from the data base.  The mutations have been 
grouped with regard to the early and late onset of the disease 
as reported for the rare homozygous WD patients.  A third 
group has contained the mutations that have been found in 
WD patients showing intermediate (neither early nor late) 
time of the disease onset which is predominantly observed in 
the two frequently found mutations – H1069Q and R969Q. 
The mutations have been stably expressed in mammalian 
cell line of Chinese hamster ovary (CHO) that lacks intrinsic 
ATP7B expression.  The analysis of ATP7B protein expression 
and cell growth has been made for 12 cell lines.  The data on 
the functional characterization of ATP7B mutant cell lines 
have been compared to the clinical presentation reported for 
the homozygous WD patients.
Material and methods
Mutations phenotype
The data on most patients have been derived from the 
literature search of Pubmed, Medline, HGMD.  The criteria 
for the selection of mutations have been the presence of a 
homozygous ATP7B allelic variant and the availability of 
clinical information about the time of the disease onset and 
the predominant clinical presentation in patients having it. 
Ten mutations have been arbitrarily chosen.  Two mutations 
of WD patients, who have been studied during the last 10 
years, have been chosen from Klinische und Experimentelle 
Transplantationshepatologie, Universitätsklinikum Münster 
(UKM) data base.  The clinical parameters, laboratory data, 
and ATP7B mutation analysis have been evaluated by UKM 
clinicians according to the common guidelines (Ferenci 2003). 
The data are summarized in table 1.  The genomic DNA has 
been extracted from the peripheral blood samples.  The blood 
has been obtained after getting the informed consent, and all 
procedures have been approved by the local Ethics Review 
Board.  Twenty one exons of the WD gene have been ampli-
fied, and the sequencing of the polymerase chain reaction 
(PCR) products has been performed using the Taq DyeDeoxy 
Terminator Cycle Sequencing Kit (Applied Biosystems) with 
an ABI-Prism 3100 genetic analyzer (Applied Biosystems).
Generation of mutant ATP7B cell lines
The studies have been carried out using CHO cells lacking 
ATP7B, which were obtained from the German tissue culture 
collection (DSMZ) and cultivated in 5% CO2 at 37°C in humid 
atmosphere.  The culture medium used has been DMEM 
F12 (Lonza), 10% FCS (PAA), 1% penicilline-streptomycine 
(PAA), 0.075% sodium bicarbonate (Lonza).  Plasmid pGCsa-
mENATP7B has been cloned into retroviral vector (kind gift 
of O. Wildner, Ruhr Universität Bochum) using cDNA that 
contained human wild type cDNA of ATP7B [32].  Plasmid 
pGCsamENATP7B has been mutagenized using the primers 
by means of site-directed mutagenesis (QuikChange II XL 
site-directed mutagenesis kit, Stratagene).  The mutagenized 
cDNA has been sequenced using an Applied Biosciences 3100 
sequencer to confirm the presence of the selected variant 
and the absence of secondary mutations.  The sequence of 
ATP7B in the cell lines has been also confirmed at the end of 
the experiment.  The retroviral vectors have been generated 
as reported above [32].  The transductions of CHO cells have 
been carried out in the presence of polybrene (Sigma-Aldrich). 
The stable cell lines have been selected by gentamycin (Gibco; 
400 µg/ml) that has been included into the tissue culture me-
dium during the cultivation of the cells.  The CHO cells that 
carried empty vector, untransduced CHO cells and CHO cells 
harboring wild type pGCsamENATP7B plasmid have been 
used as control ones.
Western Blot analysis
The cells have been grown in a tissue culture dish, rinsed 
twice with ice cold Phosphate Buffered Saline (PBS; produced 
by PAA company) and incubated for 10 min on ice in the lysis 
buffer (1% Triton X-100, 30 mM Tris, pH 8.0, 75 mM NaCl, 7.5 
mM EDTA, 1% Na-deoxycholate, 2.5% SDS) using protease 
inhibitor cocktail (Complete; Roche Applied Science).  The 
cell lysate has been collected by scraping and incubated for 15 
min on ice followed by a centrifugation at 14,000 rpm at 4°C 
for 30 min.  20 µg of protein has been divided into fractions 
on a 9% SDS polyacrylamide gel and blotted onto nitrocel-
lulose membrane (Amersham Hybond ECL; GE Healthcare 
Life Sciences).  The membrane has been blocked in PBS 
containing 0.1% Tween 20 (produced by USB) and 5% fat 
free dry milk (AppliChem) at 4°C overnight.  After washing 
five times with 0.05% Tween/PBS the membrane has been 
incubated with polyclonal rabbit anti-ATP7B (kind gift of Dr. 
I. Sandoval, Madrid, Spain) diluted 1:2 000 in 0.1% Tween/
PBS, 3% BSA/PBS for 1.5 hours.  To control the protein load-
ing goat polyclonal antiserum – anti-HSC70 – (produced by 
Santa Cruz, # C2906) has been used.  A peroxidase-labelled 
secondary antibody produced by Sigma has been used for the 
detection by Enhanced Chemi-Luminescence (ECL) (Western 
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Blotting Detection Reagent; GE Healthcare Life Sciences).  A 
densitometric analysis has been performed using ImageQuant 
TL Plus 7.0 (GE Healthcare Life Sciences) software.  A relative 
expression has been compared to CHO cells expressing the 
wild type of ATP7B.
Cell growth
2 x 104 cells have been seeded into three wells in a 96-well 
plate (Becton Dickinson) and cultivated for 24 hours in 100 
µl of medium (DMEM high glucose without phenol red; pro-
duced by PAA company).  On the next day, at a cell confluency 
of 90-100% the medium has changed to 100µl of the same 
medium containing CuCl2.  The cells have been cultivated 
for 48 hours.  After that the cells have been washed with PBS 
once and 100 µl of MTT solution (2 mg/ml in phenol red free 
medium, Sigma) has been added.  After a 2-hour incubation 
100 µl of sodium dodecyl sulphate (15%; Sigma)/dimethyl 
sulfoxide (6 M; Roth; pH 4.5) has been added.  The optical 
density has been determined at 560 nm in a multiwell plate 
reader (Multiskan EK, Thermo Labsystems) after a 24-hour 
incubation of the plates at room temperature.  For each cell line 
three 96-well plates have been analysed in the experiments. 
Three independent experiments have been performed.  The 
Table 1
ATP7B Variants Evaluated for Copper Transport Activity in CHO cells
Protein posi-
tion
Age
of onset
Clinic
Exon Location Type Postulated effect KF ringGastro
intestinal
Neurological
G
ro
up
E
p.E583R fs 5 Dystonia tremors 5 Cu 6 Frameshift +
p.T766R 17 Severe dysarthria 8 TM 4 Missense +
p.G691R 7-9 Liver cirrhosis 7 TM 2 Missense +/-
p.G1341D 5 20 TM7 Missense
p.L1071W 8 Dysarthria 14 ATP N-binding +
G
ro
up
L
p.R616Q 38, 55 Ataxia,
Dysarthria
5 Cu 6 Conservative ami-
no acid change
+
p.A874V 27, 34 11 TD
p.T1288R 30 Liver cirrhosis 18 ATP hinge
G
ro
up
I
p.H1069Q + 14 ATP loop
SEPHL
Missense Disruptive ATP 
binding
p.R969Q 8-9
20±11
Hepatic 
cirrhosis
13 Tm5 Tm6 Missense -
p.C1079Y 8-11 Dysarthria,
dystonia
14 ATP N-binding
p.I1102T 11 Chronic liver 
disease
+ 15 ATP N-binding
results of the mutant cells have been calculated as a percentage 
of the respective cells that received no copper (100%).
Results
Establishment of stable cell lines expressing mutants 
of ATP7B
Twelve mutations observed in ATP7B homozygous pa-
tients showing different clinical manifestation of WD have 
been selected from the literature as well as from UKM data 
base (tab. 1).
Eleven missense and one frame shift mutation (E583R-
fs) have been located throughout the open reading frame of 
ATP7B (fig. 1).
For our study ATP7B mutations have been grouped ac-
cording to the reported onset of the disease observed in the 
respective homozygous patients (tab. 1).  The first two groups 
have contained mutations observed in the reports of early or 
sudden (E583R-fs, G691R, T766R, L1071W and G1341D), or 
late (R616Q, A874V and T1288R) onset of the disease (groupE 
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Fig. 1.  Scheme of ATP7B protein, featuring the N-terminal domain (Wilson’s disease copper-binding 
domain) and the 6 N-terminal metal binding sites marked Cu1-Cu6, the phosphatase (A-domain), 
phosphorylation (P-domain) and ATP-binding (N-domain).  The cylindrical regions labeled Tm1-Tm8 represent 
the trans-membrane domains.  Selected mutation sites are marked. 
 
For our study ATP7B mutations have been grouped according to the reported onset of the disease 
observed in the respective homozygous patients (tab. 1).  The first two groups have contained 
mutations observed in the reports of early or sudden (E583R-fs, G691R, T766R, L1071W and 
G1341D), or late (R616Q, A874V and T1288R) onset of the disease (groupE and groupL, 
respectively).  The third group of the mutations has contained the mutations R969Q, H1069Q, 
C1079Y and I1102T that have been reported for WD patients predominantly showing an 
intermediate onset of the disease (groupI).  Most mutations have been reported in a few patients (n < 
5) and families while mutations R969Q and H1069Q have been more frequently observed.  To 
generate stable cell lines that express mutant ATP7B CHO cells that lack ATP7B expression have 
been chosen.  Untransduced CHO cells and CHO cells expressing ATP7B wild type have been used 
as a reference for the determination of the biologic ATP7B function during the study. 
ATP7B mutant cell lines display highly characteristic growth curves at elevated copper 
concentrations 
To assure that the biologic function of the ATP7B mutant cell lines is a valid methodology for the 
classification of the functional ATP7B activity the growth of cell lines has been followed using 
various copper concentrations (fig. 2). 
  
 
 
Fig. 1.  Scheme of ATP7B protein, featuring the N-terminal domain 
(Wilson’s disease copper-binding domain) and the 6 N-terminal metal 
binding sites marked Cu1-Cu6, phosphatase (A-domain), phospho-
rylation (P-domain) and ATP-binding (N-domain).  The cylindrical 
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and groupL, respectively).  The third group of the mutations 
has contained the mutations R969Q, H1069Q, C1079Y and 
I1102T that have been reported for WD patients predomi-
nantly showing an intermediate onset of the disease (groupI). 
Most mutations have been reported in a few patients (n < 5) 
and families while mutations R969Q and H1069Q have been 
more frequently observed.  To generate stable cell lines that 
express mutant ATP7B CHO cells that lack ATP7B expression 
have been chosen.  Untransduced CHO cells and CHO cells 
expressing ATP7B wild type have been used as a reference 
value for the determination of the biologic ATP7B function 
during the study.
ATP7B mutant cell lines display highly characteristic 
growth curves at elevated copper concentrations
To assure that the biologic function of the ATP7B mutant 
cell lines is a valid methodology for the classification of the 
functional ATP7B activity the growth of cell lines has been 
followed using various copper concentrations (fig. 2).
 
Fig. 2. Graphical representation of the results obtained after the 
calculation of the mean value and SE after 3 independent experi-
ments (9 plates have been used).
The growth of the cells has been determined by MTT 
assay after 48 hours period.  All five ATP7B mutant cell lines 
of groupE (E583R-fs, G691R, T766R, L1071W and G1341D) 
have showed a rapid decline of cell growth at increasing 
copper concentrations that has leveled to a value of 0% at 
the copper concentrations above 0.5 mM.  The cell growth 
rates of the five cell lines have been almost identical to that 
of the CHO control cell line which lacks ATP7B expression. 
On the contrary, all three ATP7B mutant cell lines of groupL 
(R616Q, A874V and T1288R) have displayed a uniform 
growth characteristic with high cell growth rates (> 50.7 ± 2%) 
at copper concentrations above 0.5 mM.  The growth rates of 
the three ATP7B mutant cell lines have very much resembled 
the values obtained with CHO cells expressing wild type of 
ATP7B.  ATP7B mutant cell lines of groupI (R969Q, H1069Q, 
C1079Y and I1102T) have displayed the growth curves that 
have been highly elevated as compared to CHO control cells 
but have had intermediate values as compared to CHO cells 
expressing wild type of ATP7B.  It’s notable that the growth 
rates of mutant cell line R969Q have been significantly lower 
at the copper concentrations above 0.5 mM (> 6.1 ± 1%) as 
compared to the other mutant cell lines of this group (> 34.5 
± 1%).  The statistical analysis of the growth rates among 
the three groups of ATP7B mutant cell lines has showed the 
highly significant differences suggesting that the biological 
activity of ATP7B mutants may fall into three distinct classes 
that mostly correlate with the onset of the disease observed 
in homozygous WD patients (tab. 1).
Highly diverse ATP7B protein expression in mutant 
cell lines
Next, the ATP7B-specific protein expression has been 
determined in ATP7B transduced CHO cell lines (fig. 3).
Fig. 3. CHO cells transfected with wild type or mutant ATP7B 
have been lysed and the protein expression has been determined 
by Western Blot analysis using anti-ATP7B and anti-actin.
Densitometric analyses of Western Blots (tab. 2) has re-
vealed that ATP7B-specific protein has been poorly expressed 
(< 5% of wild type) in groupE of mutants (E583R-fs, G691R, 
L1071W, and G1341D) with the exception of T766R (37.2 ± 
7%).  In groupL of mutants (R616Q, A874V, and T1288R) the 
high levels of ATP7B protein (up to 90%) have been detected 
as compared to CHO cells expressing ATP7B wild type (100%). 
Within groupI of mutants (R969Q, H1069Q, C1079Y, and 
I1102T) only mutant cell line H1069Q has showed moderate 
levels (18.5 ± 5%) of ATP7B protein expression while the other 
three mutants have been poorly detected (< 5% of wild type).
Table 2
Characteristics of ATP7B mutant cell lines as compared 
to the wild type
Mutant cell line
Protein Growth (1 mM Cu)
(A560 nm) 
(%)(%)
E583R-fs 0.3 ± 0 0.9 ± 1
G691R 3.4 ± 0 0.0 ± 0
T766R 37.2 ± 7 0.0 ± 0
L1071W 3.3 ± 1 0.3 ± 0
G1341D 2.3 ± 1 0.0 ± 0
R616Q 77.3 ± 8 89.5 ± 4
A874V 35.3 ± 8 82.7 ± 3
T1288R 84.7 ± 6 90.8 ± 3
R969Q 2.3 ± 1 9.4 ± 4
H1069Q 18.0 ± 5 56.7 ± 9
C1079Y 0.3 ± 0 63.3 ± 11
I1102T 3.3 ± 1 62.4 ± 2
The percentage has been calculated relative to CHO 
expressing ATP7B wild type.  Mean value ± SE of 3-6 expe-
rimets are shown.  The value of CHO background has not 
been considered.
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Discussion
Many mutations have been reported in some patients 
without the knowledge of their impact on the course of WD. 
This is the first report on the functional characterization of 
ATP7B mutations in a cohort of WD patients having rare ho-
mozygous mutations.  A high correlation has been observed 
between ATP7B protein expression, cell growth and the time 
of the disease onset.  The early onset and most severe disease 
have correlated with an almost complete lack of the respective 
ATP7B activities in transgenic tissue culture cells.  A late onset 
of the disease has correlated with high ATP7B activities which 
almost reached levels of the wild type ATP7B.  An intermediate 
time of the disease onset with mostly milder disease has been 
found in the group of mutations showing intermediate activi-
ties of ATP7B.  The in vitro characterization of the ATP7B 
activities, as it has been established in this study, has allowed 
us to single out the distinct groups of mutations that have 
similar biologic activity correlating to the onset of the disease. 
The functional classification of ATP7B mutations may have 
importance for the disease prognosis of patients, at least in 
the subset of homozygous WD patients and may also further 
extend our knowledge about the molecular principles of the 
wide phenotypic variations observed in individual mutations 
including H1069Q and R969Q.
Various exogenous expression systems have been used to 
analyze the function of ATP7B mutations including the cell 
lines of yeast, insect cells and mammalian tissue culture de-
rived from e.g. human kidney or liver [29, 14, 15].  CHO cells 
used for our study proved to be well suited for the analysis of 
ATP7B function [11, 18].  Generally the trafficking of ATP7B 
through different cellular compartments with regard to cop-
per concentration has been studied while various mutations 
have also been characterized by biochemical and biological 
analyses including the assessment of copper toxicity, copper 
retention and growth.  According to our knowledge this is 
the first report combining two functional characterizations of 
ATP7B in a set of mammalian mutant cell lines.  The molecular 
mechanisms leading to the rescue from toxic copper in hepa-
tocytes and in extrahepatic cells is not completely understood, 
the current knowledge suggests that the copper is transferred 
by complex mechanisms including trafficking of the copper 
mediated by ATP7B to a location of reduced oxidative stress, 
e.g. by incorporation of the copper into vesicles and/or by 
the copper secretion (Singleton 2010).  The highly concord-
ant results of the two functional assays that have determined 
a cellular growth at elevated copper concentrations have 
been mostly observed in a given cell line.  Interestingly, two 
ATP7B mutant cell lines, L1071W and G1341D, have showed 
the low but significantly elevated values of copper retention 
while the growth has been severely impaired suggesting that 
the capability to accumulate the copper within the cells is a 
different functional entity of transgenic ATP7B as compared 
to the escape of the cell growth at high copper concentration.
A lot has been learned about the association of the ATP7B 
genotype and phenotype by means of studying the patient 
cohorts.  The most studied mutation in such cohorts, H1069Q 
mutation, has however got rather conflicting results of the 
study.  Yet a predominately later onset of the disease and neu-
rological presentation have been observed in many H1069Q 
homozygous patients’ different clinical manifestations, e.g. 
early and severe hepatic disease has been noticed in other 
patients [22, 9, 34, 6, 10, 33].  It is, therefore, interesting that 
our functional characterization of H1069Q has showed rather 
high activity for a mutant protein of ATP7B suggesting that 
a moderate activity of ATP7B may represent a prerequisite 
for the observed wide spectrum of clinical presentations 
which are likely caused by the secondary disease modifying 
factors.  Thus, the classification of ATP7B activity as shown 
here may predict the overall possibility of a given mutation 
to be modulated by the secondary disease modifying factors 
that are obviously operational in the patients.  In this line, the 
diverse clinical presentations observed in R969Q mutation of 
this group might also be associated to the intermediate ATP7B 
activity observed in this mutant.  Mutations E583R-fs, G961R, 
T766R, L1071W and G1341D that have been proved to have 
significantly reduced ATP7B activity may, thus, have a more 
limited spectrum of phenotypic presentations and mutations 
of this group might, therefore, be predominately associated 
with an early onset of the disease.  The mutations belonging 
to the group that have retained a high ATP7B activity close 
to the level observed in the wild type (R616Q, A874V and 
T1288R) may, thus, be associated to a later onset and a milder 
disease.  It should be noted, however, that the extrapolation of 
our findings is limited to WD patients having the respective 
homozygous mutation.  In addition, our conclusions are based 
on a limited number of mutations and some of the chosen 
mutations have been obtained from the patients that may 
show a region-specific phenotype.  However, the cell culture 
approach that has been used here to classify the mutations 
possibly excludes the influence of many disease-modifying 
factors that may reside in the 80 kb ATP7B gene and elsewhere, 
e.g. in the variations of the promoter region, splicing events, 
polymorphisms (SNPs), differences in poly-adenylation se-
quences and the influence caused by environmental factors. 
Such analysis of ATP7B activity, therefore, seems to be valuable 
to predict the impact of a given mutation in the absence of 
disease-modifying factors.
Two of the missense mutations (E583R-fs and R616Q) 
studied here are located in copper binding domain 6 of ATP7B. 
The deletion studies have shown that the last two copper bind-
ing domains (Cu5 and Cu6) are required for copper transport 
across membranes while the other copper binding domains 
may have a regulatory role [13, 1, 15].  The mutation E583R-
fs leads to a premature stop of the protein translation.  Such 
mutations have been implicated to result in early and severe 
disease by analysis of WD cohorts; however, these findings 
have been challenged by others [12, 22, 28, 24, 25, 27].  As it is 
shown here, the expression of ATP7B cDNA encoding a frame 
shift mutation leads to a complete loss of ATP7B activities sug-
gesting that in the absence of disease-modifying factors such 
mutations are likely to cause a severe disease as opposed to the 
missense mutations that retain a residual biologic activity of 
ATP7B.  The second mutation of the Cu6 domain (R616Q) is 
a missense mutation that has been described in two separate 
homozygous patients with a late onset and a mild phenotype 
of WD.  The change of the bulky amino acids arginine to 
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glutamine at amino acid position 616, therefore, has had only 
a low impact on ATP7B activity.
Four mutations studied here are located within (G691R, 
T766R and G1341D) or between (R969Q) the trans-mem-
brane regions of ATP7B.  The three of these mutations (G691R, 
T766R and G1341D) are found to have a highly reduced ac-
tivity of ATP7B.  The homozygous mutation G691R is found 
in a large family in Lebanon with a severe hepatic disease 
and the early time of the disease onset [4].  The homozygous 
mutation T766R is found in a patient that showed a sudden 
severe onset of the disease with a neurologic manifestation 
[30].  The homozygous mutation G1341D has been observed 
in the patients from Eastern Europe having an early onset of 
the disease and a severe hepatic/neurologic manifestation. 
The mutations located within the trans-membrane region of 
ATP7B may, thus, significantly reduce the biologic activity 
of ATP7B.  In contrast to the three mutations which have 
showed almost no biologic activity of ATP7B, the mutation 
R969Q has showed an intermediate activity of ATP7B.  The 
homozygous mutation R969Q is frequently found and has 
been also observed in the families from Pakistan and Greece 
having a variety of mostly hepatic disease manifestations that 
have included the asymptomatic course of the disease as well 
as a rapid progression to a fulminant disease [28].
The mutation A874V that is located in the transduction 
domain (A domain) of ATP7B has had almost no detrimen-
tal effect on ATP7B activity.  The mutation A874V is com-
monly found in Asian cohorts and a homozygous mutation 
A874V has been observed in the families having hepatic and 
hepatic-neurological diseases with a late onset [17].  The 
mutation T1288R is located in P domain (hinge region) and 
has not showed a significant impact on ATP7B activity.  The 
homozygous mutation T1288R has been observed in a family 
from Sicilia that has showed a late onset of a hepatic disease 
with no signs of a neurologic syndrome [19].
Four mutations are located in the adenosine triphos-
phate (N-domain) of ATP7B important for copper binding. 
The mutation L1071W has almost completely lost ATP7B 
activities while the other mutations (H1069Q, C1079Y and 
I1102T) have showed an intermediate ATP7B activity.  The 
homozygous mutation L1071W has been observed in a family 
that showed an early onset of a severe neurological disease, and 
it has been suggested that the bulky amino acid tryptophan in 
position 1071 can significantly affect the activity of ATP7B. 
Notably, the homozygous mutation H1069Q, C1079Y and 
I1102T have been found in the patients having a broad range 
of mostly intermediate time of the disease onset.  Our find-
ing of a moderately reduced ATP7B activity of the mutation 
H1069Q located in N domain is supported by other biochemi-
cal characterizations.  The configuration of the ATP binding 
site is not affected by this mutation although the affinity of 
N-domain to ATP is markedly decreased [8, 23].
Conclusions
The results indicate that the characterization of ATP7B 
activity in mammalian cell cultures has resulted in the 
classification of mutants having distinct degrees of biologic 
activity which correlate with the onset of the disease in rare 
homozygous WD patients.
For the two frequently found mutations, H1069Q and 
R969Q, an intermediate ATP7B activity has been observed, 
what contributes to our understanding of the role of the 
disease-modifying factors for the clinical presentation in the 
group of mutations having significant residual activity.  An 
early onset and most severe disease has been observed in the 
group of mutations having none or marginal ATP7B activity 
including one frame shift mutation.
The prediction of the onset of the disease worked out 
by the functional classification may not be applicable on an 
individual basis; the characterization of ATP7B mutations as 
it is demonstrated here may help to further understand the 
general impact of a mutation, e.g. of novel mutations obser-
ved in young ATP7B homozygous patients where the clinical 
phenotype of WD may not be fully developed.
In order to achieve a higher accuracy while predicting the 
course of the disease and to gain more knowledge concerning 
the protein function more tests are to be made, for example, 
regarding ATP7B protein stability, copper retention, copper 
induced toxicity.
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Abstract
Background: Non-Hodgkin’s lymphomas (NHLs) are a heterogenous group of malignant tumors developing from the lymphoid tissue and having 
a wide range of clinical manifestations and varied evolution and prognosis.
Material and methods: We have studied the clinical peculiarities of 228 patients of different age groups with NHLs and a primary involvement of 
lymph nodes.
Results: The frequency of the lymph nodes primary involvement has constituted 37.6%.  It has been established that NHLs most frequently had their 
primary onset in the peripheral lymph nodes (61.8%), less frequently – in the abdominal (23.3%) and mediastinal (14.9%) ones.  NHLs most frequently 
begin their development in the peripheral lymph nodes, first in patients over 60 years old (84.6%), in the abdominal lymph nodes – in children (57.2%), 
in the mediastinum – in children and people aged between 19 and 39 (48.2%).
Conclusions: Children develop only aggressive NHL forms, these forms also predominate in adults.  Aggressive NHLs in adults have been most often 
diagnosed in the patients having the primary tumor focus location in the mediastinal and abdominal lymph nodes.  The frequency of indolent NHLs is 
higher in the cases with the primary involvement of the peripheral lymph nodes, the patients’ age being over 60.  Metastases in the bone marrow have 
most frequently been recorded in NHL patients with the primary involvement of peripheral lymph nodes (53.5%).  The involvement of CNS has taken 
place most frequently in the patients with NHLs, having the onset in the abdominal (34.4%) and mediastinal (30.0%) lymph nodes.
Key words: non-Hodgkin’s lymphomas, lymph nodes, age.
